Compare VYGR & LAZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | LAZR |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4M | 80.2M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | LAZR |
|---|---|---|
| Price | $4.39 | $0.90 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 3 |
| Target Price | ★ $17.00 | $1.00 |
| AVG Volume (30 Days) | 469.2K | ★ 5.6M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,316,000.00 | ★ $75,753,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.97 |
| 52 Week Low | $2.65 | $0.78 |
| 52 Week High | $6.55 | $10.40 |
| Indicator | VYGR | LAZR |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 42.07 |
| Support Level | $3.74 | $0.85 |
| Resistance Level | $4.51 | $1.04 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 84.94 | 33.67 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.